Is R-MDMA a Safer Version of MDMA?
Author Information
Author(s): I. Straumann, I. Avedisian, A. Klaiber, N. Varghese, A. Eckert, D. Rudin
Primary Institution: Centre for Youth Mental Health, University of Melbourne, and Orygen, Melbourne, Australia
Hypothesis
S-MDMA will produce greater subjective stimulation than R-MDMA, and that R-MDMA will produce greater psychedelic-like effects relative to S-MDMA.
Conclusion
The study suggests that R-MDMA may not be safer than racemic or S-MDMA for clinical use.
Supporting Evidence
- S-MDMA increased subjective ratings of feeling stimulated relative to both doses of R-MDMA.
- S-MDMA increased ratings of several prosocial mood states compared to R-MDMA.
- R-MDMA did not produce stronger psychedelic-like effects than S-MDMA or racemic MDMA.
- All active conditions caused similar transient adverse effects during the sessions.
- Neuroendocrine responses were preferentially increased after S-MDMA.
Takeaway
This study looked at whether a different version of MDMA, called R-MDMA, is safer than the regular MDMA. It found that R-MDMA didn't work as well as hoped.
Methodology
A double-blind, placebo controlled, cross-over design was used to compare the effects of R-MDMA, S-MDMA, racemic MDMA, and placebo.
Potential Biases
The lack of weight-based dosing may introduce bias in the effects observed between male and female participants.
Limitations
The study had limitations including potential dose inequivalence and lack of weight-based dosing.
Participant Demographics
Participants were 24 healthy adults with equal representation of women and men.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website